Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Kenya cancer research and control stakeholder program: Evaluating a bilateral partnership to strengthen national cancer efforts.

Journal of cancer policy·2023
Same author

A cross-sectional analysis of factors associated with detection of oncogenic human papillomavirus in human immunodeficiency virus-infected and uninfected Kenyan women.

BMC infectious diseases·2019
Same author

Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Long-term toxicity of cisplatin in germ-cell tumor survivors.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients.

Annals of oncology : official journal of the European Society for Medical Oncology·2016

Related Experiment Video

Updated: Jul 15, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Drugs five years later. Cisplatin.

P J Loehrer, L H Einhorn

    Annals of Internal Medicine
    |May 1, 1984
    PubMed
    Summary

    Cisplatin, a chemotherapy drug, effectively treats testicular cancer. Modern supportive care has greatly reduced its side effects, allowing for broader clinical application and ongoing research into its use.

    Area of Science:

    • Medical Chemistry
    • Oncology
    • Pharmacology

    Background:

    • Cisplatin is a platinum-based chemotherapy agent.
    • Initially approved for testicular cancer, it has demonstrated significant efficacy.
    • Early treatments were limited by severe gastrointestinal and renal toxicities.

    Purpose of the Study:

    • To review the current understanding of cisplatin's pharmacology and mechanism of action.
    • To discuss the management of cisplatin-induced toxicities.
    • To explore ongoing research into cisplatin analogues and administration variations.

    Main Methods:

    • Literature review of clinical studies and pharmacological data.
    • Analysis of toxicity profiles and management strategies.
    • Examination of ongoing research trends in cisplatin therapy.

    More Related Videos

    Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
    09:52

    Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

    Published on: March 16, 2018

    Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
    09:40

    Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

    Published on: August 2, 2024

    Related Experiment Videos

    Last Updated: Jul 15, 2026

    Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
    04:04

    Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

    Published on: February 12, 2017

    Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
    09:52

    Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

    Published on: March 16, 2018

    Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
    09:40

    Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

    Published on: August 2, 2024

    Main Results:

    • Cisplatin exhibits broad-spectrum anticancer activity.
    • Modern antiemetic therapies and hydration protocols significantly mitigate toxicity.
    • Enhanced understanding of cisplatin's pharmacokinetics and pharmacodynamics.

    Conclusions:

    • Cisplatin remains a vital chemotherapeutic agent for testicular cancer.
    • Improved supportive care has enhanced patient tolerance and treatment outcomes.
    • Further research is focused on optimizing cisplatin's efficacy and minimizing adverse effects through analogue development and administration adjustments.